Skip to content
★ Sign in to follow
Isofol Medical AB (publ) logo

Isofol Medical AB (publ) Stock: price and insider trades · Sweden

ISIN SE0025197528SE·Mcap SEK 284.6MHealth Care

1 insider bought €4,292 of shares over the last 90 days, the latest by Helena Taflin, filed 09 Oct 2026.

Isofol Medical AB (publ): what insiders have been doing

Every trade that managers of Isofol Medical AB (publ) disclose to Finansinspektionen is tracked on this page. The company sits in the Health Care sector. Between 30 October 2025 and 30 October 2026, 2 insiders published 2 filings.

No insider sold shares on the market over the period. Instead, the filings list 2 purchases totalling €13k, made by 2 insiders. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Petter Segelman Lindqvist filed the largest purchase, €8,441, on 15 June 2026. The buyers include 1 board member and 1 chief executive.

For context, the typical company on the same exchange (median of 1,034 companies) published 9 filings over the same period, against 2 filings here. Since 2025, the database holds 4 purchases and 1 sale by insiders of the company.

The last insider purchase was made public on 9 October 2026, 30 days ago.

For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and EssilorLuxottica. This summary is built from Finansinspektionen disclosures alone and does not predict where the share price will go.

Insider Decl.
7
Thresholds
n/a
Buy Volume
€17,666
4 ops. · all time
Sell Volume
€271
1 ops. · all time

Who traded when

BuySale
Petter Segelman Lindqvist1 buy1 sale
Helena Taflin1 buy
Margareta Hagman1 buy
Roger Tell1 buy

Financial data

as of FY 2025

FY ended December 2025 · cache

SEK 0.89
Analyst consensus
1 analysts
0.00/5
SEK 1.70Target SEK 1.70(+91%)SEK 1.70
Income statement
EBITDA-SEK 54.2M
Net income-SEK 54.2M0.0% margin
Valuation
PER (forward)-29.6x
P/Book3.0x
Beta1.02
Balance sheet & cash
Market capSEK 284.6M
Total debtSEK 3.9M
Free Cash Flow-SEK 51.9M
Profitability & ownership
ROE-78.3%
ROA-39.0%
% insiders26.1%
% institutions15.0%
Last declaration on 9 October 2026
Declarations7 total
  • ▲
    StyrelseledamotExecutives
    48,510 SEK22FI-SE
    63,000 shares@ SEK 0.770.019% mcap100.0% of flowAktieISIN SE0009581051FI:csv-ff15a3f3a3fac506cce9
    Canonical exit: 4 Jan 2027 (T+90)
  • ▲
    Verkställande direktör (VD)Executives
    92,300 SEK0FI-SE
    1,000,000 shares@ SEK 0.092378.3% of flowTeckningsoptionFI:csv-91908161023c21b62fee
    Canonical exit: 13 Sept 2026 (T+90)
  • ▲
    Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
    51,950 SEK0FI-SE
    5,000 shares@ SEK 10.39100.0% of flowBTU (betald tecknad unit)ISIN SE0025197536FI:A003Q419-1
    Canonical exit: 1 Oct 2025 (T+90)
  • ●
    Verkställande direktör (VD)Executives
    23,155 SEK0FI-SE
    2,412 shares@ SEK 9.6019.1% of flowBTU (betald tecknad unit)ISIN SE0025197536FI:A003Q427-1
  • ●
    Ekonomichef/finanschef/finansdirektörExecutives
    69,331 SEK0FI-SE
    7,222 shares@ SEK 9.6095.0% of flowBTU (betald tecknad unit)ISIN SE0025197536FI:A003Q438-1
  • ▲
    Ekonomichef/finanschef/finansdirektörExecutives
    3,600 SEK0FI-SE
    90,000 shares@ SEK 0.045.0% of flowTeckningsrätt/UniträttISIN SE0025197528FI:A003Q300-1
    Canonical exit: 25 Sept 2025 (T+90)
  • ▼
    Verkställande direktör (VD)Executives
    3,007 SEK0FI-SE
    33,408 shares@ SEK 0.092.5% of flowTeckningsrätt/UniträttISIN SE0025197528FI:A003Q152-1

7 of 7 declarations

About Isofol Medical AB (publ)

Isofol Medical AB (publ) is a Swedish biopharmaceutical company focused on developing treatments for cancer. It is listed on the Stockholm Stock Exchange (XSTO).

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations